RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HitGen, a Chengdu drug discovery/development company, closed a $39 million Series B financing led by CDH, a Beijing VC/PE firm, and Leadyond Capital, a PE firm also based in Beijing. So far, HitGen has established over 50 active drug discovery collaborations with pharmaceutical companies based on its DNA-encoded library, which consists of 900 individual libraries and over 200 billion novel small molecules. The company plans to use the proceeds to expand its drug discovery technology platform and accelerate the R&D of its in-house therapeutic development programs.
Source: China Biotoday
